Results 141 to 150 of about 70,369 (254)

Heterogenous Model of Temozolomide Resistance in Glioblastoma Reveals Phenotypic Shifts in Drug Response and Migratory Potential

Advanced NanoBiomed Research, Volume 6, Issue 6, June 2026.
Glioblastoma mortality is driven by cell invasion and therapeutic resistance. We report a cancer engineering approach to evaluate the behavior of heterogeneous cohorts of temozolomide resistant and responsive GBM cells. We show the effect of physiologically‐relevant metronomic dosing on ensemble drug response and invasion.
Victoria A. Kriuchkovskaia, Ela K. Eames, Sydney A. McKee, Paul J. Hergenrother, Rebecca B. Riggins, Brendan A. C. Harley   +5 more
wiley   +1 more source

Metastatic Ewing Sarcoma, Patterns of Care and Outcomes of Patients in a Real‐Life National Setting Over a Decade

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT Metastatic Ewing sarcoma (MES) has a poor prognosis. This multicenter observational study provides real‐world data on treatment patterns of patients with MES in France. Treatment characteristics, outcomes such as time to next treatment (TTNT) and overall survival (OS), and prognostic factors of patients aged ≥ 12 years treated for a MES in 11 ...
Coline Ducrot, Derek Dinart, Maeva Bonneau, Max Piffoux, Marie Sophie Minot, Juliane Mignot‐Posson, Thomas Grinda, Jordane Chaix, Sarah Winter, Pauline Gerard, Romain Duong, Berengère Narciso, Natacha Entze Werle, Cécile Vérité, Valérie Laurence, Axel Le Cesne, Pablo Berlanga, Camille Tlemsani, Pascaline Boudou‐Rouquette, Emmanuelle Bompas, Thibaud Valentin, Nadège Corradini, Mehdi Brahmi, Carine Bellera, Maud Toulmonde   +24 more
wiley   +1 more source

Analysis of Treatment Patterns for Mucosal Melanoma Using Real‐World Data in the SEER‐Medicare–Linked Database

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT Background Mucosal melanoma (MM) is a rare, aggressive disease, often diagnosed late, and associated with poor survival. Surgical resection is the main potential curative option, but anatomical complexity limits feasibility, and real‐world evidence on treatment patterns remains scarce.
Marjan Zakeri, Samuel Wagner, Xianxin Zhu, Onur Baser   +3 more
wiley   +1 more source

C1orf226 Promotes Glioma Stemness and Oncogenesis in Glioma via PLK1‐Mediated Wnt/β‐Catenin Signaling

Cancer Medicine, Volume 15, Issue 6, June 2026.
High C1orf226 expression correlates with glioma aggressiveness and worse prognosis. C1orf226 promotes malignant phenotypes and stemness in glioma cells. C1orf226 interacts with PLK1 to stabilize β‐catenin and activate the Wnt/β‐catenin pathway. ABSTRACT Introduction Glioma stem cells (GSCs) are pivotal drivers of tumor progression and therapeutic ...
Yanbing Lu, Chao Jiang, Hongfei Wu, Junkui Shang, Bin Wang, Shundong Cang, Jiewen Zhang   +6 more
wiley   +1 more source

Temozolomide and treatment of malignant glioma

Malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) occur more frequently than other types of primary central nervous system tumors, having a combined incidence of 5-8/100,000 population.
A. H., H. S., T., Friedman, Kerby, Calvert   +5 more
core  

Temozolomide reconsidered: Real-World evidence in resistant melanoma cases. [PDF]

Oncologist
Maselli-Schoueri JH, Martinez E, Lagos E, Campos EF, Saldanha EF, Muniz TP, Butler MO, Saibil SD.   +7 more
europepmc   +1 more source

Bilateral Thalamic Diffuse Midline Glioma, H3K27M‐Altered, in a 3‐Year‐Old Boy

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Diffuse midline glioma, H3 K27‐altered, is an aggressive pediatric brain tumor that can mimic non‐neoplastic conditions when located outside the brainstem. We describe a 3‐year‐old boy who presented with progressive ocular misalignment and left‐sided weakness without systemic symptoms.
Ammir Abuzahra, Bessan N. Abuzahra, Ruba Atawneh, Siwar Abu Sakout, Raya Abu Ayyash, Jana Dwaik, Mohammad Y. Nairokh, Nasim Abukaresh   +7 more
wiley   +1 more source

Homeobox B13 activates the hypoxia‐inducible factor 1 pathway through histone lactylation thereby reprogramming lipid metabolism and promoting sorafenib resistance in hepatocellular carcinoma

Journal of Cell Communication and Signaling, Volume 20, Issue 2, June 2026.
Lactylation‐mediated metabolism reprogramming in HCC sorafenib resistance. In sorafenib‐resistant hepatocellular carcinoma (HCC) cells, lactate accumulation drives histone H3 lysine 18 lactylation (H3K18la). This modification is specifically enriched in the promoter region of homeobox B13 (HOXB13), activating HOXB13 transcription and upregulating its ...
Qingqing Xie, Fangxia Teng, Ting Ding, Huaizhe Zhang, Jian Huang, Shu Zhang   +5 more
wiley   +1 more source

Advancements in Glioblastoma Multiforme Treatment: A Comprehensive Systematic Review and Meta-Analysis. [PDF]

Brain Behav
Agboola K, Khafaji F, Chaurasia B, Qureshi K, Yangi K, Chavda V, Balak N.   +6 more
europepmc   +1 more source

Lysine lactylation‐mediated post‐translational modification: Molecular mechanisms and therapeutic target exploration in tumour drug resistance

Clinical and Translational Medicine, Volume 16, Issue 6, June 2026.
Lysine lactylation (Kla) serves as a metabolic–epigenetic switch governed by writer–eraser–reader regulatory systems, directly connecting the Warburg effect to diverse forms of tumour drug resistance. Intratumoural lactylation critically contributes to treatment failure in chemotherapy, targeted therapy and immunotherapy.
Juan Li, Yan Shang, Haojie Wu, Shenglong Yang, Maiqun Zuo, Hailong Zhao   +5 more
wiley   +1 more source